Immunotherapy before surgery for early-stage colon cancer
Part of Cancer, Digestive system clinical trials.
This trial tests whether giving immunotherapy (pembrolizumab) before surgery can help treat stage I-III colon cancer that has a specific genetic feature (dMMR). The goal is to see if this approach can reduce the amount of surgery needed or improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have colon cancer that has not spread far (stage I, II, or III) and has a specific genetic marker called dMMR.
- Your doctor has planned surgery to remove the cancer, and it is not an emergency.
- You are in generally good health (able to do daily activities without major limitations).
- You do not have any condition that would make pembrolizumab unsafe for you, such as a known allergy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests how long you need a PD-1 immunotherapy before surgery for a specific type of rectal cancer (dMMR/MSI-H). It looks at whether a shorter or longer course works best. This could mean fewer side effects and a quicker path to surgery.
This trial tests if the immunotherapy drug pembrolizumab can shrink colon cancers with specific genetic features (dMMR/MSI-H) before surgery. If the tumor responds well, some patients might avoid chemotherapy after surgery. It is for people with newly diagnosed, localized colon or upper rectal cancer.
This trial tests pembrolizumab (an immunotherapy medicine) given before curative surgery in people with certain MMR-deficient colon or rectal cancers. It aims to shrink or control the cancer so surgery can be done more effectively, and to see if outcomes improve compared with standard care.
This trial tests a new immunotherapy drug (tislelizumab) given before surgery for people with stage II or III colorectal cancer that has a specific DNA repair problem (dMMR/MSI-High). The drug aims to shrink the tumor and improve treatment outcomes.
This phase 2 trial tests whether injecting a vaccine into the tumor, along with pembrolizumab (an immune medicine), can improve outcomes for people with early-stage, localized colon cancer that does not have certain DNA mismatch repair changes (pMMR). It’s done around the time you plan to have curative surgery, with the goal of boosting the immune system against the cancer.
This Phase 2 trial tests immune “checkpoint” medicines (and combinations) given before colon surgery to see if they can better control early colon cancer. It is aimed at people with non-metastatic colon cancer and certain tumor markers.
Hear when a new DMMR Colorectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.